Form 4: Director Donenberg Receives Stock Options
Statement of Changes in Beneficial Ownership
Phillip B. Donenberg, a Director at Sensei Biotherapeutics, Inc., was granted 23,100 stock options as a supplemental grant to align with the company's compensation policy.
Summary
- Phillip B. Donenberg, a Director of Sensei Biotherapeutics, Inc., received a supplemental stock option grant of 23,100 shares on April 10, 2026.
- This grant is intended to bring his total initial director option grant in line with the company's amended non-employee director compensation policy, which provides for 25,000 shares for new directors.
- Donenberg had previously received an initial grant of 1,900 shares in February 2026.
- The options have an exercise price of $29.89 and are set to expire on April 9, 2036.
- The options vest over a three-year period, with full vesting occurring on April 10, 2029, contingent upon Donenberg's continuous service to the company.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation adjustment for a director rather than a significant operational or financial event.
Positives
- Alignment of director compensation with company policy ensures fair and competitive remuneration.
- The supplemental grant demonstrates the company's commitment to its board members.
- The vesting schedule over three years incentivizes long-term commitment and performance.
Risks
- The value of the stock options is subject to market fluctuations and the company's future performance.
- Vesting is contingent on continuous service, meaning any departure before full vesting would result in forfeiture of unvested options.
Future Outlook
The stock options granted are subject to vesting over three years, with full vesting on April 10, 2029, contingent on the reporting person's continuous service. The options expire on April 9, 2036.
Industry Context
StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology sector to attract and retain experienced leadership, aligning their interests with shareholders through equity participation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Policy Amendment | The company amended its non-employee director compensation policy on April 10, 2026, to provide for an initial option grant of 25,000 shares to new directors. | 04/10/2026 | Ensures competitive compensation for directors and aligns their incentives with long-term company performance. |
| Power of Attorney | Phillip B. Donenberg executed a Power of Attorney appointing Christopher Gerry and Josiah Craver as his legal representatives to prepare and file Forms 3, 4, and 5 with the SEC. | 04/13/2026 | Facilitates efficient and timely compliance with SEC reporting requirements for beneficial ownership changes. |
Stakeholder Impact
- Shareholders: The issuance of options aligns director interests with shareholder value creation, but also dilutes ownership slightly upon exercise.
- Employees: The compensation policy update may indirectly influence employee compensation strategies.
- Management: The supplemental grant reinforces the company's commitment to its board members.
Next Steps
- Phillip B. Donenberg will continue to serve as a Director.
- The stock options will vest over a three-year period, subject to continuous service.
- The company will continue to operate under its non-employee director compensation policy.
Key Dates
| Date | Description |
|---|---|
| 02/XX/2026 | Previous initial grant of 1,900 shares to Phillip B. Donenberg. |
| 04/10/2026 | Date of supplemental stock option grant and earliest transaction date. |
| 04/09/2029 | Full vesting date for the supplemental stock option grant. |
| 04/09/2036 | Expiration date of the stock options. |
| 04/13/2026 | Date of execution for the Power of Attorney. |
| 04/14/2026 | Date of filing for Form 4 and Power of Attorney. |
Keywords
Form 4, Stock Options, Director Grant, Sensei Biotherapeutics, SNSE, Insider Trading, Beneficial Ownership, Compensation Policy
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.